OBJECTIVE: Little is known about long-term viral suppression rates for patients who start antiretroviral therapy (ART) soon after diagnosis. We describe virologic outcomes from the San Francisco-based Ward 86 Rapid ART Program for Individuals with an HIV Diagnosis (RAPID) ART program. DESIGN: Retrospective review of clinic-based cohort. METHODS: In 2013, Ward 86 adopted immediate ART at the first visit after HIV diagnosis. Patients were referred from testing sites, offered same or next-day intakes, and received multidisciplinary evaluation, support, and insurance enrollment/optimization. Patients were provided ART starter packs and close follow-up. Demographics and labs were extracted from medical records. Subsequent viral loads were obtained from public health surveillance data. Kaplan-Meier curves summarized distribution of times to first viral suppression; viral suppression rates at last viral load recorded were calculated. RESULTS: Of 225 patients referred to RAPID ART from 2013 to 2017, 216 (96%) were started on immediate-ART: median age 30; 7.9% women; 11.6% African-American, 26.9% Hispanic, 36.6% white; 51.4% with substance use; 48.1% with mental health diagnoses; 30.6% unstably housed; baseline median CD4 cell count 441 cells/μl median viral load 37 011. By 1 year after intake, 95.8% achieved viral suppression to less than 200 cells/μl at least once. Over a median follow-up time of 1.09 years (0-3.92), 14.7% of patients had viral rebound, but most (78%) resuppressed. Viral suppression rates were 92.1% at last recorded viral load. CONCLUSION: In an urban clinic with high rates of mental illness, substance use and housing instability, immediate ART provided through a RAPID program resulted in viral suppression at last viral load measurement for more than 90% of patients over a median of 1.09 years. RAPID ART for vulnerable populations is acceptable, feasible, and successful with multidisciplinary care and municipal support.
OBJECTIVE: Little is known about long-term viral suppression rates for patients who start antiretroviral therapy (ART) soon after diagnosis. We describe virologic outcomes from the San Francisco-based Ward 86 Rapid ART Program for Individuals with an HIV Diagnosis (RAPID) ART program. DESIGN: Retrospective review of clinic-based cohort. METHODS: In 2013, Ward 86 adopted immediate ART at the first visit after HIV diagnosis. Patients were referred from testing sites, offered same or next-day intakes, and received multidisciplinary evaluation, support, and insurance enrollment/optimization. Patients were provided ART starter packs and close follow-up. Demographics and labs were extracted from medical records. Subsequent viral loads were obtained from public health surveillance data. Kaplan-Meier curves summarized distribution of times to first viral suppression; viral suppression rates at last viral load recorded were calculated. RESULTS: Of 225 patients referred to RAPID ART from 2013 to 2017, 216 (96%) were started on immediate-ART: median age 30; 7.9% women; 11.6% African-American, 26.9% Hispanic, 36.6% white; 51.4% with substance use; 48.1% with mental health diagnoses; 30.6% unstably housed; baseline median CD4 cell count 441 cells/μl median viral load 37 011. By 1 year after intake, 95.8% achieved viral suppression to less than 200 cells/μl at least once. Over a median follow-up time of 1.09 years (0-3.92), 14.7% of patients had viral rebound, but most (78%) resuppressed. Viral suppression rates were 92.1% at last recorded viral load. CONCLUSION: In an urban clinic with high rates of mental illness, substance use and housing instability, immediate ART provided through a RAPID program resulted in viral suppression at last viral load measurement for more than 90% of patients over a median of 1.09 years. RAPID ART for vulnerable populations is acceptable, feasible, and successful with multidisciplinary care and municipal support.
Authors: Niklaus D Labhardt; Isaac Ringera; Thabo I Lejone; Thomas Klimkait; Josephine Muhairwe; Alain Amstutz; Tracy R Glass Journal: JAMA Date: 2018-03-20 Impact factor: 56.272
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272
Authors: Serena P Koenig; Nancy Dorvil; Jessy G Dévieux; Bethany L Hedt-Gauthier; Cynthia Riviere; Mikerlyne Faustin; Kerlyne Lavoile; Christian Perodin; Alexandra Apollon; Limathe Duverger; Margaret L McNairy; Kelly A Hennessey; Ariadne Souroutzidis; Pierre-Yves Cremieux; Patrice Severe; Jean W Pape Journal: PLoS Med Date: 2017-07-25 Impact factor: 11.069
Authors: Nathan Ford; Chantal Migone; Alexandra Calmy; Bernhard Kerschberger; Steve Kanters; Sabin Nsanzimana; Edward J Mills; Graeme Meintjes; Marco Vitoria; Meg Doherty; Zara Shubber Journal: AIDS Date: 2018-01-02 Impact factor: 4.177
Authors: Jonathan Colasanti; Jeri Sumitani; C Christina Mehta; Yiran Zhang; Minh Ly Nguyen; Carlos Del Rio; Wendy S Armstrong Journal: Open Forum Infect Dis Date: 2018-06-28 Impact factor: 3.835
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Susan J Little; Tom Chen; Rui Wang; Christy Anderson; Sergei Kosakovsky Pond; Masato Nakazawa; William C Mathews; Victor DeGruttola; Davey M Smith Journal: Clin Infect Dis Date: 2021-09-07 Impact factor: 9.079
Authors: April C Pettit; Latrice C Pichon; Aima A Ahonkhai; Cedric Robinson; Bruce Randolph; Aditya Gaur; Andrea Stubbs; Nathan A Summers; Kimberly Truss; Meredith Brantley; Rose Devasia; Michelle Teti; Sarah Gimbel; Julia C Dombrowski Journal: J Acquir Immune Defic Syndr Date: 2022-07-01 Impact factor: 3.771
Authors: Jesse G O'Shea; Julia W Gallini; Xiangqin Cui; Abeer Moanna; Vincent C Marconi Journal: AIDS Patient Care STDS Date: 2022-05-18 Impact factor: 5.944
Authors: Elizabeth Imbert; Matthew D Hickey; Angelo Clemenzi-Allen; Elizabeth Lynch; John Friend; Jackelyn Kelley; Madellena Conte; Doyel Das; Jan Bing Del Rosario; Erin Collins; Jon Oskarsson; Mary Lawrence Hicks; Elise D Riley; Diane V Havlir; Monica Gandhi Journal: AIDS Date: 2021-07-01 Impact factor: 4.632